James Alan Simon MD

Obstetrics & Gynecology•Washington, DC

General Gynecology, Reproductive Endocrinology & Infertility

Clinical Professor of Obstetrics & Gynecology, Geo Wash University

Join to View Full Profile

1850 M St NWSte 450Washington, DC 20036
Phone+1 202-293-1000
Fax+1 202-463-6150

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Reproductive Endocrinology and Infertility, 1984
George Washington UniversityResidency, Obstetrics and Gynecology, 1978 - 1982
Rush Medical College of Rush University Medical CenterClass of 1978

Certifications & Licensure

CA State Medical License 1982 - Present
DC State Medical License 1979 - 2027
MI State Medical License 2024 - 2027
OH State Medical License 2024 - 2026
VA State Medical License 1979 - 2026
CO State Medical License 2024 - 2025
TN State Medical License 2024 - 2025
MD State Medical License 1979 - 2009
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Reproductive Endocrinology/Infertility
American Association of Sex Educators, Counselors and TherapistsCertified Sexuality Counselor
International Society for Clinical DensitometryCertified Clinical Densitometrist
International Society for the Study of Women's Sexual HealthISSWSH Fellow
North American Menopause SocietyNAMS Certified Menopause Practitioner
Join now to see all

Awards, Honors, & Recognition

Top Washington Physician
Best Doctors In America
America’s Top Obstetricians and Gynecologists
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) Start of enrollment: 2011 May 01
Completed
Phase 3
Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo Start of enrollment: 2012 Mar 01
Completed
Phase 3
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Start of enrollment: 2015 Dec 22
Completed
Phase 3
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Start of enrollment: 2016 Sep 14
Completed
Phase 3
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Start of enrollment: 2017 Jun 30
TERMINATED
PHASE3
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain Start of enrollment: 2017 Jul 07
COMPLETED
PHASE3
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Start of enrollment: 2017 Jan 04
COMPLETED
PHASE3
Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis Start of enrollment: 2018 Jul 04
Terminated
Phase 2
Dysport in Vulvodynia Phase II Study Start of enrollment: 2018 Jun 11
Terminated
Phase 2
Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles Start of enrollment: 2021 Oct 26
COMPLETED
PHASE3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

State of the art in menopause: current best practice approaches from the IMS World Congress 2024, Melbourne.
James A Simon, Susan R Davis, Angelica Lindén Hirschberg, Ludwig Kiesel, Luciano de Melo Pompei
Climacteric. 2025-04-01
Testosterone for Treating Female Sexual Dysfunction.
James A Simon, Kathleen Ohleth
Clinical Obstetrics and Gynecology. 2025-03-01
Glucagon-like peptide-1 agonist weight loss medications decrease sexual desire: a theoretical framework based in the serotonergic pathway.
Meghan C Tveit, Sonya T Gelfand, James A Simon
The Journal of Sexual Medicine. 2025-01-09

Press Mentions

Testosterone Therapy for Menopause: What the Hormone Can, and Cannot, DoFebruary 4th, 2025
Long-Term Data Support Non-Hormonal Drug for Hot-Flash ManagementSeptember 15th, 2024
Data from Phase III Study OASIS 3 Support Efficacy and Long-Term Safety of Investigational Compound Elinzanetant in the Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseSeptember 10th, 2024
Join now to see all